Form 4: Citius Pharma CEO Extends Warrants, Updates Holdings

Sentiment:

Statement of Changes in Beneficial Ownership 23 September 2025 4:05 PM

📋All filings for Citius Pharmaceuticals, INC

Citius Pharmaceuticals CEO Leonard L. Mazur extended the expiration dates of two tranches of warrants and updated his beneficial ownership of common stock and stock options.

Summary

Leonard L. Mazur, CEO and Director of Citius Pharmaceuticals, Inc., reported changes in his beneficial ownership.
He beneficially owns 410,214 shares of Citius Pharmaceuticals Common Stock directly.
Two tranches of warrants were amended on August 8, 2025, extending their expiration dates by one year.
The first warrant tranche, for 125,490 shares with an exercise price of $28.75, had its expiration date extended from August 14, 2025, to August 14, 2026.
The second warrant tranche, for 89,388 shares with an exercise price of $19.25, had its expiration date extended from September 27, 2025, to September 27, 2026.
The filing also details various stock options held by Mr. Mazur, with exercise prices ranging from $9.5 to $86.25 and expiration dates extending to November 7, 2034.
Some stock options are fully vested and immediately exercisable, while others vest over a three-year period.
All share amounts reported reflect a 1-for-25 reverse stock split effective November 22, 2024.

Sentiment

Score: 6

Explanation: The extension of warrant expiration dates by one year for a significant number of shares suggests the CEO sees potential for the stock price to appreciate over a longer horizon. This can be interpreted as a positive signal of management's confidence. However, the high exercise prices for both warrants and some stock options mean substantial stock price growth is required for these to be profitable, which introduces a degree of risk.

Positives

Extension of warrant expiration dates provides Mr. Mazur with more time to exercise these options, potentially allowing him to benefit from future stock price appreciation.
The continued holding of a significant number of common shares and stock options by the CEO indicates alignment of interests with shareholders.

Negatives

The exercise prices for the extended warrants ($28.75 and $19.25) are relatively high, suggesting the stock price would need to appreciate significantly for these warrants to be in-the-money.
Some stock options also have high exercise prices, such as $86.25, which may be challenging to reach.

Risks

The value of the warrants and stock options is contingent on the future performance of Citius Pharmaceuticals' stock price. If the stock price does not exceed the exercise prices, these derivatives may expire worthless.
The company's stock price could be volatile, impacting the potential profitability of exercising these derivatives.

Future Outlook

The extension of warrant expiration dates to August 14, 2026, and September 27, 2026, indicates a forward-looking expectation by the reporting person to potentially exercise these warrants in the future. Stock options have expiration dates extending to November 7, 2034, reflecting long-term incentive structures.

Industry Context

This filing is a routine insider transaction report and does not provide broader industry context or trends.

Related Party Transactions

The warrant amendments and stock option grants are transactions between the company and its CEO, which are inherently related-party transactions as part of executive compensation.

Stakeholder Impact

Shareholders: The extension of warrants by the CEO could be viewed as a signal of management's long-term confidence in the company's prospects, potentially influencing investor sentiment.
Employees: The vesting schedules for stock options are tied to continuous service, aligning the CEO's long-term incentives with the company's performance.

Next Steps

The vesting schedules for certain stock options indicate future milestones for the reporting person to maintain continuous service to the company to fully vest these options.

Key Dates

Date	Description
08/13/2018	Original issuance date of the first warrant tranche.
09/27/2019	Original issuance date of the second warrant tranche.
10/04/2022	Grant date of stock options with $31.25 exercise price.
10/10/2023	Grant date of stock options with $17.5 exercise price.
11/07/2024	Grant date of stock options with $9.5 exercise price.
11/22/2024	Effective date of 1-for-25 reverse stock split.
08/08/2025	Transaction date for warrant amendments.
08/14/2025	Original expiration date of the first warrant tranche.
09/23/2025	Signature date of the filing.
09/27/2025	Original expiration date of the second warrant tranche.
08/14/2026	New expiration date of the first warrant tranche.
09/27/2026	New expiration date of the second warrant tranche.
09/13/2027	Expiration date of stock option with $86.25 exercise price.
09/04/2028	Expiration date of stock option with $40.5 exercise price.
10/08/2029	Expiration date of stock option with $16.75 exercise price.
10/06/2030	Expiration date of stock option with $25.25 exercise price.
07/22/2031	Expiration date of stock option with $50 exercise price.
10/11/2031	Expiration date of stock option with $51 exercise price.
10/04/2032	Expiration date of stock option with $31.25 exercise price.
10/10/2033	Expiration date of stock option with $17.5 exercise price.
11/07/2034	Expiration date of stock option with $9.5 exercise price.

Recommendation

hold

This Form 4 primarily details the extension of existing warrants and the status of stock options for the CEO. While the warrant extensions could be seen as a minor positive signal of management's long-term view, the high exercise prices for many of the derivatives mean significant stock appreciation is required. There are no new material financial disclosures or strategic shifts that would warrant a strong buy or sell recommendation based solely on this filing. It's a routine update on insider holdings, suggesting a "hold" position to await more substantive company news or financial results.

Keywords

Citius Pharmaceuticals, CTXR, Form 4, Insider Trading, Beneficial Ownership, Warrants, Stock Options, Leonard L. Mazur, CEO, Director, Reverse Stock Split

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.